Last reviewed · How we verify

NCT00151931

Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis

Completed Phase 3 Last updated 8 June 2021
What this trial tests

Phase 3 trial testing Lanthanum carbonate in Kidney Failure, Chronic in 456 participants. Completed in 12 January 2006.

Timeline
11 May 2004
Primary endpoint
12 January 2006
12 January 2006

Quick facts

Lead sponsorShire
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment456
Start date11 May 2004
Primary completion12 January 2006
Estimated completion12 January 2006

Drugs / interventions tested

Conditions studied

Sponsor

Shire — full company profile →

Who can join

18 and older, any sex, with Kidney Failure, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lanthanum carbonate

Trials testing the same drug.

Other recruiting trials for Kidney Failure, Chronic

Currently open trials in the same condition.

Other Shire trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00151931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing